Breeze Holdings Acquisition CORP 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
Breeze Holdings Acquisition Corp. stockholders have approved the business combination with YD Biopharma Limited, paving the way for the combined entity, YD Bio Limited, to trade on Nasdaq under the ticker YDES.
Breeze Holdings Acquisition Corp. shareholders approved an extension of the deadline to complete a business combination until September 26, 2025, amidst significant share redemptions and a reduced trust account balance.
Breeze Holdings Acquisition Corp.'s publicly traded warrants and rights will transition from the OTCQX to the OTCQB market after failing to meet continued listing requirements, though its common stock remains on OTCQX and its business combination plans proceed.
8-K: Breeze Holdings Acquisition Corp. Boosts PIPE Investment for YD Biopharma Merger to $30 Million
Breeze Holdings Acquisition Corp. announced an amendment to its merger agreement with YD Biopharma Limited, significantly increasing the Private Investment in Public Equity (PIPE) commitment from $15 million to $30 million.
Breeze Holdings Acquisition Corp. reported the immediate resignation of Bill Stark from its board of directors due to personal reasons, reducing the board size from seven to six members.
8-K: Breeze Holdings Acquisition Corp. Changes Accounting Firms: Marcum LLP Resigns, CBIZ CPAs Engaged
Breeze Holdings Acquisition Corp. announces the resignation of Marcum LLP as its independent registered accounting firm and the engagement of CBIZ CPAs P.C., effective April 2, 2025.
Breeze Holdings Acquisition Corp. received a notice from OTCQX Market regarding non-compliance with continued listing requirements related to its rights and warrants, with a deadline to cure the deficiency by June 13, 2025.
Breeze Holdings Acquisition Corp. received notice of non-compliance with OTCQX listing requirements and faces potential delisting unless the deficiency is cured by June 13, 2025.
Breeze Holdings Acquisition Corp. has successfully extended the deadline to complete a business combination to June 26, 2025, following a shareholder vote and subsequent amendment to its charter.
Breeze Holdings Acquisition Corp. has announced a definitive agreement to merge with YD Biopharma, a clinical-stage biopharmaceutical company, in a deal that values the combined entity at nearly $700 million.
Breeze Holdings Acquisition Corp.'s merger agreement with TV Ammo was terminated by TV Ammo, ending the planned business combination.
Breeze Holdings Acquisition Corp. successfully extended its deadline to complete a business combination to December 26, 2024, following a shareholder vote.
Breeze Holdings Acquisition Corp. will be delisted from Nasdaq after failing to complete its business combination by the May 28, 2024 deadline.
Breeze Holdings Acquisition Corp. has been granted an extension by Nasdaq to complete its initial business combination by May 28, 2024, to avoid delisting.
Breeze Holdings Acquisition Corp. has entered into an amended and restated merger agreement with True Velocity, Inc. and TV Ammo, Inc., setting the stage for a business combination expected to close in the second quarter of 2024.